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Abstract
Background and aim: Spontaneous rupture of hepatocellular carcinoma (HCC) carries a high mortality. The use of
radiofrequency ablation (RFA) in recent years has enriched the armamentarium for hemostasis of spontaneously ruptured
HCCs but its results have not been documented. This study investigated the prognosis and outcome of spontaneous
rupture of HCC as well as the results of using RFA for hemostasis.
Patients and method: From January 1991 to December 2010, 5283 patients were diagnosed with HCC at our hospital, and
189 of them had spontaneous rupture of HCCs. They were grouped under two periods: period 1, 1991–2000, n = 70; period
2, 2001–2010, n = 119. RFA was available in period 2 only.
Results: Hepatitis B virus infection was predominant in both periods. Surgical hemostasis was mainly achieved by hepatic
artery ligation in period 1 and by RFA in period 2. The 30-day hospital mortality after surgical treatment was 55.6% (n = 18)
in period 1 and 19.2% (n = 26) in period 2 (p = 0.012). Multivariate analysis identified 4 independent factors for better overall
survival, namely, hemostasis by transarterial chemoembolization (hazard ratio 0.516, 95% confidence interval 0.354–0.751),
hemostasis by RFA (hazard ratio 0.431, 95% confidence interval 0.236–0.790), having surgery as a subsequent treatment
(hazard ratio 0.305, 95% confidence interval 0.186–0.498), and a serum total bilirubin level ,19 umol/L (hazard ratio 1.596,
95% confidence interval 1.137–2.241).
Conclusion: The use of RFA for hemostasis during laparotomy greatly reduced the hospital mortality rate when compared
with conventional hepatic artery ligation.
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Introduction
Spontaneous rupture is one of the presentations of hepatocel-
lular carcinoma (HCC). It can have catastrophic consequences.
The incidence of spontaneous rupture of HCCs ranges from 3–
14.5% in regions where HCC is prevalent [1–4]. Transarterial
chemoembolization (TACE) is a well-established treatment option
[5,6]. Emergency hepatic artery ligation, plication, packing,
hepatectomy or radiofrequency ablation (RFA) is required if
TACE fails to achieve hemostasis [3,4]. Unfortunately, many
patients having surgical intervention end up in liver failure or even
death. This study tried to find out whether using RFA for
hemostasis during laparotomy would improve patients’ hospital
survival.
Patients and Methods
From January 1991 to December 2010, 5283 patients were
diagnosed with HCC and 189 of them had spontaneous rupture of
HCCs and were admitted to our hospital. All the data used in this
study were recorded by a single research assistant. The 189
patients were grouped under two periods: period 1, 1991–2000,
n = 70; period 2, 2001–2010, n= 119.
Ethics statement
The study complies with the laws of Hong Kong and follows the
principles laid down in the Declaration of Helsinki. Oral consent
by the patients was obtained after clear and complete explanation
and was recorded in the patients’ medical records. Approval in the
form of written consent was not needed as it was waived by the
institutional review board of The University of Hong Kong, which
approved this retrospective study.
Treatment algorithm
Diagnosis of spontaneous rupture of HCCs was based on
clinical pictures acquired by physical examination and screening
ultrasonography on presentation. Shock index was used to
describe the hemodynamic status of a patient. Shock index was
calculated as the division of heart rate reading by systolic blood
pressure reading. The shock index of a healthy adult should be in
the range between 0.5 and 0.7. A patient was classified as in shock
when his/her shock index was .0.7 [7].
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Figure 1. Treatment algorithm for spontaneous rupture of HCCs.
doi:10.1371/journal.pone.0094453.g001
Table 1. Demographics, liver function and clinical presentations of patients.
1991–2000 (n =70) 2001–2010 (n=119) P
Median age (years) 59.5 (13–94) 58 (34–92) 0.557
Male: Female 57:13 88:31 0.240
Presence of comorbidity 23 (32.9%) 48 (40.3%) 0.305
Child-Pugh class 0.997
A 30 (46.2%) 55 (46.2%)
B 26 (40.0%) 48 (40.3%)
C 9 (13.8%) 16 (13.4%)
Median Model for End-stage Liver Disease score 12.75 (6–27) 10.94 (6–37) 0.522
Median albumin (g/L) 32 (13–52) 34 (12–46) 0.332
Median total bilirubin (umol/L) 21 (6–750) 18 (4–180) 0.272
Median international normalized ratio 1.2 (0.9–3.2) 1.15 (0.9–4.1) 0.514
Median aspartate transaminase (U/L) 103 (23–1710) 93 (21–1003) 0.946
Median alanine transaminase (U/L) 54.5 (13–652) 50 (5–679) 0.221
Median creatinine (umol/L) 94 (46–379) 93 (8–296) 0.328
Median a-fetoprotein (ng/mL) 2055.5 (2–1720600) 636.5 (2–1451000) 0.236
Median tumor size (cm) 10 (2–23) 8.5 (2–30) 0.619
Hepatitis B virus infection 42 (60.0%) 86 (72.9%) 0.001
Peritoneal irritation or severe abdominal pain 49 (70.0%) 93 (78.2%) 0.211
Shock 33 (47.1%) 51 (42.9%) 0.674
Drop in hemoglobin .2 g/dL or hemoglobin ,10 g/dL on initial blood test 46 (65.7%) 81 (68.1%) 0.739
doi:10.1371/journal.pone.0094453.t001
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Contrast computed tomography of the abdomen was performed
for patients without renal impairment. Patients with any one of the
following three conditions were managed conservatively: (a) major
portal vein tumor thrombosis, (b) disseminated extrahepatic
disease, (c) Karnosfsky performance status ,40%. Other patients
were treated according to our standard treatment protocol
(Figure 1).
TACE
TACE was conducted by experienced interventional radiolo-
gists. Selective cannulation of the feeding artery of the tumor was
attempted. Embolization of the feeding artery was performed by
injection of pellets (162 mm) mixed with 40 mg of gentamycin
and contrast. Depending on the size and number of tumor, 4–
20 mL of gelfoam emulsion was injected into the catheter placed
in the artery supplying the tumor or, for bilobar disease, into the
hepatic artery proper beyond the gastroduodenal artery. Gelfoam
injection was stopped when the blood flow in the artery supplying
the tumor slowed down and occlusion occurred. Relative
contraindications to TACE included main portal vein thrombosis,
arteriovenous shunting and Child-Pugh C cirrhosis [8].
Operative treatment
All operations were conducted by experienced hepatobiliary
surgeons. A bilateral subcostal incision with an upward midline
incision was performed in most of the patients. Abdominal packing
was performed. Depending on the size of the ruptured tumor and
the surgeon’s clinical judgement [4,9,10], hemostasis was attempt-
ed by (a) direct suture of the bleeding site, (b) selective hepatic
artery ligation, (c) ligation of the common trunk of the hepatic
artery, (d) hepatectomy, or (e) RFA (available in period 2 only). If
hepatectomy was required, hepatic parenchymal transection was
conducted with an ultrasonic dissector. The Pringle maneuver
Table 2. Operative and postoperative details and mortality rates.
1991–2000 (n=18) 2001–2010 (n =26) P
Laparotomy without TACE 15 (83.3%) 20 (76.9%) 0.890
Common hepatic artery ligation 1 (5.6%) 0 0.852
Left or right hepatic artery ligation 12 (66.7%) 3 (11.5%) 0.0001
Direct suture 3 (16.7%) 1 (3.8%) 0.357
Tumor resection 2 (11.1%) 2 (7.7%) 1
Coagulation by argon beam 6 (33.3%) 12 (46.2%) 0.395
Hemostasis by RFA 0 19 (73.1%) ,0.0001
Median blood loss (L) 3 (0.8–13) 2.2 (0.2–7.8) 0.355
Median operation time (min) 115 (75–225) 140 (90–255) 0.102
Median intensive care unit stay (d) 2 (0–16) 2 (0–25) 0.761
Median hospital stay (d) 13 (1–34) 14.5 (0.46–52) 0.872
Complication (Clavien-Dindo grade)
3a 2 (11.1%) 3 (11.5%) 1
3b 0 1 (3.8%) 1
4a 1 (5.6%) 1 (3.8%) 1
5 10 (55.6%) 6 (23.1%) 0.028
Mortality for hepatic artery ligation 8/13 (61.5%) 2/3 (66.7%) 1
Hospital mortality for ruptured HCC 10 (55.6%) 6 (23.1%) 0.028
30-day mortality for ruptured HCC 10 (55.6%) 5 (19.2%) 0.012
doi:10.1371/journal.pone.0094453.t002
Table 3. Details of RFA for hemostasis.
Tumor ,5 cm (n=4) Tumor 5–10 cm (n=8) Tumor .10 cm (n=7) P
Median tumor size (cm) 3.5 (3.0–4.5) 5.6 (5.0–9.1) 13.5 (11.1–19.0) 0.001
Tumor number 0.253
1 3 (75%) 2 (25.0%) 3 (42.9%)
2 1 (25%) 3 (37.5%) 0
.2 0 3 (37.5%) 4 (57.1%)
Median ablation time (min) 22 (12–22) 17 (12–49) 32 (12–72) 0.222
No. of patients who had the Pringle maneuver 0 1 (12.5%) 0
Time of the Pringle maneuver (min) - 60 -
doi:10.1371/journal.pone.0094453.t003
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might be applied during the procedure. All patients who received
operative treatment were managed in the intensive care unit.
RFA
RFA was available in period 2 only. It was performed by
hepatobiliary surgeons experienced in using the RFA device.
Direct puncturing of the bleeding site was performed in most of
the cases. A single needle or clustered needles (maximum array
diameter 4.0 cm) were used according to the size of the tumor. For
most bleeding tumors, a cluster probe was used. RFA was
administered using the Olympus Cool-tip system, which consists of
a generator that supplies up to 200 W of power until satisfactory
hemostasis is achieved [11,12].
Statistical analysis
The baseline characteristics of patients were expressed as
medians and ranges. The Mann-Whitney U test was used to
compare continuous variables, and Pearson’s chi-squared test was
used to compare discrete variables. Hospital mortality was defined
as death occurring after admission to and before discharge from
Figure 2. a. Overall hospital mortality of patients with spontaneously ruptured HCCs. b. Hospital mortality of patients who had surgery for
spontaneously ruptured HCCs. c. Hospital mortality of patients who had TACE as the primary treatment for spontaneously ruptured HCCs. d. Hospital
mortality of patients who had conservative management alone for spontaneously ruptured HCCs.
doi:10.1371/journal.pone.0094453.g002
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hospital. Survival curves were computed with the Kaplan-Meier
method and compared between groups by the log-rank test. The
logistic regression analysis was performed to define factors that
affected hospital mortality. The Cox proportional hazards model
was used to define factors that determined the 30-day mortality
rate. Statistical significance was denoted by a p value ,0.05. All
statistical calculations used the computer software SPSS/PC+
(SPSS, Chicago, IL, USA).
Results
The rate of spontaneous rupture of HCC in period 1 was 3.7%
(70/1892) and 3.5% (119/3391) in period 2. Demographics, liver
function and clinical presentations of the 189 patients are shown in
Table 1. In period 1, 33 (47.1%) patients received TACE as the
first treatment, 15 (21.4%) patients received surgery as the first
treatment, and 22 (31.4%) patients received conservative man-
agement. Hemostasis by TACE failed in 3 patients and they
subsequently received surgery. In period 2, 58 (48.7%) patients
received TACE as the first treatment, 20 (16.8%) patients received
surgery as the first treatment, and 41 (34.5%) patients received
conservative management. Hemostasis by TACE failed in 6
patients and they subsequently received surgery.
In period 1, the rate of successful hemostasis was 78.8% (26
patients) for TACE, 77.8% (14 patients) for surgery, and 63.6%
(14 patients) for conservative management. In period 2, the rate of
successful hemostasis was 75.9% (44 patients) for TACE, 92.3%
(24 patients) for surgery, and 58.5% (24 patients) for conservative
management. In period 2, surgical hemostasis was mainly
achieved by RFA. Operative and postoperative details and
mortality rates in the two periods are shown in Table 2.
In period 2, 19 patients received RFA for hemostasis (Table 3).
They had a median tumor size of 8.25 cm (range 3–19 cm). Eight
(42.1%) patients had 1 tumor, 4 (21.1%) patients had 2 tumors,
and 7 (36.8%) patients had .2 tumors. Single-needle probe was
applied on 2 (10.5%) occasions and cluster-needle probe was
applied on 17 (89.5%) occasions. The median ablation time was
22 min (range 12–72 min). Only 1 patient, who had a 10-cm
tumor, received the Pringle maneuver during ablation, and the
total inflow occlusion time was 60 min. Six (31.6%) patients who
received RFA for hemostasis were found to have complete tumor
ablation on computed tomography one month after the ablation.
The 30-day hospital mortality rate of patients who had surgery
was 55.6% in period 1 and 19.2% in period 2 (p= 0.012). The 30-
day hospital mortality rate of patients who had TACE as the first
treatment was 11.5% in period 1 and 6.8% in period 2 (p = 0.81).
The 30-day hospital mortality rate of patients who had conser-
vative management was 18.2% in period 1 and 24.4% in period 2
(p = 0.805). Figures 2a-2d show the 60-day survival curves of
different groups of patients in the two periods.
In period 1, 11 patients had tumor resection after spontaneous
rupture of tumors. Five of them had minor hepatectomy and 6 had
major hepatectomy (resection of .3 liver segments). In period 2,
14 patients had tumor resection after spontaneous rupture of
tumors. Four of them had minor hepatectomy and 10 had major
hepatectomy. In period 2, 11 patients had RFA and 1 patient had
high-intensity focused ultrasound ablation [13,14] for their HCCs.
One patient had liver transplantation at another hospital.
The median survival of patients with spontaneous rupture of
HCCs was 1.61 months (range 0–178 months) in period 1 and
3.84 months (range 0–118 months) in period 2 (p = 0.474). Sixteen
patients in period 1 and 19 patients in period 2 received TACE as
a subsequent treatment. Figures 3a–3c show the 5-year survival
curves of different groups of patients in the two periods.
Thirteen independent factors that might affect the survival
outcome were analyzed (Table 4). The 6 independent risk factors
for poor survival were (a) tumor size .10 cm, (b) intolerance of
TACE for hemostasis, (c) unsuitability for subsequent surgery,
(d) poor Child-Pugh grade, (e) serum total bilirubin level .19
umol/L, and (f) international normalized ratio .1.2.
On multivariate analysis by the Cox regression model, 4
independent factors for improved survival were identified (Table 5).
They were (a) hemostasis by TACE, (b) hemostasis by RFA, (c)
having surgery as a subsequent treatment, and (d) a serum total
bilirubin level ,19 umol/L.
Discussion
To our knowledge, this study has the largest series of patients
with cirrhosis and spontaneously ruptured HCCs. Spontaneous
rupture is not the most common clinical presentation of HCCs but
it can lead to catastrophic consequences. In the study, 3.7% and
3.5% of the HCC patients in period 1 and period 2 respectively
had spontaneous rupture of tumors. Compared with the historic
figure of 14.5% published by Ong et al. [9], there was a drastic
Figure 3. a. Overall survival of patients with spontaneously ruptured HCCs. b. Overall survival of patients who had hepatectomy or RFA for
spontaneously ruptured HCCs. c. Overall survival of patients who had TACE for spontaneously ruptured HCCs.
doi:10.1371/journal.pone.0094453.g003
Outcome of Ruptured HCCs Treated by RFA
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reduction of this clinical manifestation. Early screening of patients
with hepatitis B virus infection might have allowed detection of
HCC at an early stage. The use of more sophisticated imaging
modality like dual-tracer positron emission tomography/comput-
ed tomography could have subjected more patients to surgery
when the tumors were still small [15,16].
The management of spontaneously ruptured HCCs remains
difficult because patients often present with very poor physical
conditions including coagulopathy and hemodynamic instability
[17,18]. A clear and comprehensive treatment protocol for these
scenarios is essential. TACE remains as the first-line hemostatic
option for patients with a relatively stable hemodynamic condition
[19–21]. TACE is considered highly effective in hemostasis for
ruptured HCCs. In the study, the rates of successful hemostasis in
the two periods were comparable. However, the ischemic effect of
TACE on cirrhotic livers might have contributed to liver failure,
leading to a hospital mortality of 20–30% in the entire period.
In period 1, the hospital mortality after surgery was substantial;
more than half of the patients did not survive. On the contrary,
there was a significant improvement in hospital mortality after
surgery in period 2. The operation mortality reduced to 23%. In
period 1, one of the surgical strategies for hemostasis was direct
suture of the tumour [4]. This method, however, was far from
satisfactory. Since the nature of liver tumors is quite soft, many of
the sutures might have cut through the tumors, ending up in
ineffective hemostasis. In spontaneous rupture of HCCs, the
bleeding mainly comes from the hepatic artery [22]. Selective
hepatic artery ligation was applied in period 1. Ligation of the
common hepatic artery was performed for patients with ruptured
tumors involving both lobes of the liver if selective ligation of the
hepatic artery branch had failed to stop the bleeding. Nevertheless,
successful cessation of bleeding by hepatic artery ligation could not
secure successful survival. More than 60% of the patients ended up
in hospital mortality secondary to liver failure. Neither selective
ligation of hepatic artery nor ligation of the common hepatic
artery was well tolerated in patients with advanced cirrhosis and
HCC. In period 2, selective or non-selective hepatic artery ligation
also resulted in poor survival outcomes. Three patients who had
very unstable hemodynamic condition during operation had
ligation of the hepatic artery as a last resort. Two patients
developed liver failure as a complication of hepatic artery ligation.
RFA was initially invented as an ablative tool for small HCCs in
an elective setting [23–25]. It played an important role in period 2
as a treatment for spontaneous rupture of HCCs. RFA can achieve
hemostasis and complete ablation at the same time for patients
with ruptured HCCs. For lesions ,3 cm, a single probe can
effectively achieve complete ablation [22,25,26]. A cluster probe
has an effective ablation diameter of 5 cm and is therefore suitable
for large HCCs. The effective ablation effect was demonstrated by
the fact that 3 patients with small HCCs had complete ablation of
tumors as shown by subsequent contrast computed tomography.
This study has shown that RFA is a safe and simple operative
hemostasis method that can produce an excellent survival
outcome. According to our treatment algorithm (Figure 1), TACE
is the first treatment option since it can provide effective
hemostasis with minimal invasiveness whereas RFA is the first-
line operative approach when open hemostasis is required. In the
study, RFA achieved effective hemostasis in a short period of
ablation time. It sped up the whole operation procedure and, most
importantly, it improved the overall hospital survival of patients
who required open hemostasis.
In general, RFA is safe for and well tolerated by HCC patients.
However, in patients with cirrhosis, the complication rate would
be slightly higher. As found by one of our previous studies, a
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continuous ablation time of more than 36 min might induce
intolerance in patients with cirrhosis [11]. Therefore, a long
ablation time should be avoided.
Hemostasis of large ruptured HCCs is difficult even for RFA.
For large lesions or when hemostasis could not be achieved in an
initial 12-min cycle, the Pringle maneuver should be considered as
a measure to decrease the blood flow to the lesion. In the study, a
patient who had massive bleeding from the tumor underwent the
Pringle maneuver for 60 min, and successful hemostasis was
achieved. No patient in the study developed liver failure as a
consequence of hemostasis by RFA. If RFA fails to stop tumor
bleeding, hemostasis has to be performed by other surgical means
such as hepatic artery ligation or liver resection, with an increased
risk of hospital mortality.
Liver resection can be carried out for peripheral lesions in a very
short period of time. With the advancement of laparoscopic
surgery, new technology (e.g. LigaSure), new equipment (e.g. the
Harmonic scalpel) and new linear staplers with good hemostatic
effect are available [27,28]. Theoretically these devices can speed
up the resection of peripherally located lesions. Laparoscopic liver
resection can be safely performed even in patients with cirrhosis
[29]. Two patients in the study had liver resection for lesions
located at the left lateral section with uneventful recovery.
The overall survival of HCC patients depends largely on the
stage of disease [17,30,31]. Patients in both period 1 and period 2
presented with advanced tumors and cirrhosis. On multivariate
analysis, patients with poor liver function had poorer survival.
Their poor liver function precluded them from receiving further
treatment such as locoregional therapy, targeted therapy, systemic
therapy and hepatectomy, which could prolong their survival [32–
36].
In conclusion, in the management of spontaneous rupture of
HCCs, hemostasis by RFA instead of hepatic artery ligation can
largely improve patients’ hospital survival.
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